Effects of apomorphine, ergocornine and piribedil on audiogenic seizures in DBA/2 mice
Related Experiment Videos
Abstract:
Audiogenic seizures in DBA/2 mice have been studied after administration of drugs believed to act as dopamine agonists. Apomorphine at 0.4 mg/kg delays all phases of the response, the tonic phase is absent after 2.0 mg/kg; the clonic phase is abolished by 10 mg/kg. Ergocornine (0.5-8.0 mg/kg) produces effects on the latency and occurrence of seizure stages similar to those of apomorphine. Piribedil, ET 495 (4-100 mg/kg) is less potent; even after 100 mg/kg clonic and tonic phases occurred in 50% of the mice.
Insights
Dopamine agonists like apomorphine and ergocornine can suppress audiogenic seizures in DBA/2 mice. Piribedil showed less potency in preventing these seizure phases.
Area of Science:
- Neuroscience
- Pharmacology
- Animal Models
Background:
- Audiogenic seizures are a common model for studying epilepsy.
- DBA/2 mice are a standard model for audiogenic seizures.
- Dopamine agonists are investigated for their potential anticonvulsant properties.
Purpose of the Study:
- To investigate the effects of dopamine agonists on audiogenic seizures in DBA/2 mice.
- To compare the efficacy of different dopamine agonists in suppressing seizure phases.
Main Methods:
- Administration of dopamine agonists (apomorphine, ergocornine, piribedil) to DBA/2 mice.
- Observation and recording of seizure phases (latency, tonic, clonic).
- Dose-response analysis of drug effects on seizure occurrence and severity.
Main Results:
- Apomorphine and ergocornine demonstrated dose-dependent suppression of seizure phases.
- Higher doses of apomorphine and ergocornine abolished tonic and clonic seizure phases.
- Piribedil was less potent, with 50% of mice still exhibiting seizures at the highest dose.
Conclusions:
- Dopamine agonists show significant potential in managing audiogenic seizures.
- Apomorphine and ergocornine are effective in suppressing seizure activity in this mouse model.
- Further research into dopamine pathways may yield novel epilepsy treatments.